Vancouver, BC, January 30, 2020--Chinook Therapeutics, Inc., a biotechnology company focused on developing precision medicines for kidney diseases, announced it has entered into a license agreement with AbbVie, a research-based global biopharmaceutical company, for worldwide, exclusive rights to atrasentan, an endothelin receptor antagonist.
|